

PRIOR AUTHORIZATION REQUEST FORM
Neuromyelitis Optica Spectrum Disorder (NMOSD)

For authorization, please answer each question and fax this form PLUS chart notes back to the Advantage U Prior Authorization Department at 801-213-1547.

If you have prior authorization questions, please call Advantage U for assistance: 888-605-0858

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Enspryng® (satralizumab), Ruxience® (rituximab-pvvr), Soliris® (eculizumb), Uplizna™ (inebilizumab-cdon)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Is the request made by, or in consultation with, a specialist in the treatment of neuromyelitis optica spectrum disorder (NMOSD)?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member have a confirmed diagnosis of NMOSD with positive AQP-4 antibodies and at least one core clinical characteristic such as: optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy, acute diencephalic clinical syndrome, or symptomatic cerebral syndrome with brain lesions?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Is an Expanded Disability Status Score (EDSS) score equal to 8 or less?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Has the member had at least 1 relapse that required rescue therapy in the last 12 months or 2 or more relapses that required rescue therapy in the last 24 months?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Has the member had an adequate trial and failure of any of the medications listed in this policy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

REAUTHORIZATION

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does documentation show a clinically significant response to therapy demonstrated by one of the following: <ul style="list-style-type: none"> • Decrease in relapse rate • Improvement of symptoms or stabilization of symptoms associated with relapse 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

<ul style="list-style-type: none"> Improvement in EDSS score 			
<p>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</p>			
<p>Additional information:</p>			
<p>Physician Signature:</p>			

Policy: PHARM-MA-M027
 Origination Date: 01/01/2022
 Reviewed/Revised Date: 05/18/2022
 Next Review Date: 05/18/2023
 Current Effective Date: 06/01/2022

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.